Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Operations: 2015-2024

Historic Cash from Operations for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Dec 2024 value amounting to -$113.9 million.

  • Rhythm Pharmaceuticals' Cash from Operations fell 5.58% to -$26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.1 million, marking a year-over-year increase of 12.29%. This contributed to the annual value of -$113.9 million for FY2024, which is 16.36% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Cash from Operations stood at -$113.9 million for FY2024, which was up 16.36% from -$136.2 million recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash from Operations registered a high of -$113.9 million during FY2024, and its lowest value of -$173.4 million during FY2022.
  • For the 3-year period, Rhythm Pharmaceuticals' Cash from Operations averaged around -$141.2 million, with its median value being -$136.2 million (2023).
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Cash from Operations declined by 19.69% in 2021 and then increased by 21.49% in 2023.
  • Yearly analysis of 5 years shows Rhythm Pharmaceuticals' Cash from Operations stood at -$122.0 million in 2020, then fell by 19.69% to -$146.0 million in 2021, then declined by 18.78% to -$173.4 million in 2022, then rose by 21.49% to -$136.2 million in 2023, then grew by 16.36% to -$113.9 million in 2024.